Next Century Growth Investors’s Supernus Pharmaceuticals SUPN Stock Holding History

Next Century Growth Investors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-461,467	Closed	-$5.05M	–	195
2014 Q2	$5.05M	Buy	+461,467	New	+$4.11M	0.16%	145

Other funds holding SUPN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

MRM

Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

OHCM

Orchard Hill Capital Management New York $22.6M AUM 3.52% 1-Year Est. Return

Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Next Century Growth Investors's SUPN Position: Q3 2014 in Review

Next Century Growth Investors sold out of Supernus Pharmaceuticals (SUPN) in Q3 2014, closing a stake of 461,467 shares — an estimated $5.05M sold.

Next Century Growth Investors first reported a position in SUPN in Q2 2014 and held it in 1 quarter. The position peaked at $5.05M in Q2 2014. 93 funds tracked by Wall St. Rank hold SUPN as of Q3 2014.

Next Century Growth Investors reported no remaining Supernus Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
Next Century Growth Investors sold 461,467 Supernus Pharmaceuticals shares in Q3 2014, an estimated $5.05M.
Next Century Growth Investors first reported a position in Supernus Pharmaceuticals in Q2 2014 and held it in 1 quarter.
Next Century Growth Investors's Supernus Pharmaceuticals position peaked at $5.05M in Q2 2014.
93 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2014.

Based on Next Century Growth Investors's 13F filing for Q3 2014, filed 14 Nov 2014.